City

Houston (1)

Condition

Metastatic Colorectal Adenocarcinoma (2)

Refractory Colorectal Adenocarcinoma (2)

EGFR NP_005219.2:p.S492R (1)

KRAS Gene Mutation (1)

MAP2K1 Gene Mutation (1)

Stage IV Colorectal Cancer AJCC v7 (1)

Stage IV Colorectal Cancer AJCC v8 (1)

Stage IVA Colorectal Cancer AJCC v7 (1)

Stage IVB Colorectal Cancer AJCC v7 (1)

Overall Status

Not yet recruiting (1)

Recruiting (1)

Phase

phase 1 (1)

phase 2 (1)

Sponsor

M.D. Anderson Cancer Center (1)

National Cancer Institute (NCI) (1)

Collaborator

National Cancer Institute (NCI) (1)

Study Documents

Intervention Type

biological (2)

drug (2)

other (1)

procedure (1)

Funder Type

NIH (1)

Other (1)

Study Type

Interventional (2)

refractory colorectal adenocarcinoma

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Metastatic Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8 Trial (drug,

Not yet recruiting

Metastatic Colorectal Adenocarcinoma
+2 more

BET Bromodomain Inhibitor ZEN-3694
+6 more

(no location specified)

Oct 25, 2023

EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation Trial in Houston (other, biological, drug)

Recruiting

EGFR NP_005219.2:p.S492R
+7 more

Laboratory Biomarker Analysis
+2 more

Houston, Texas

M D Anderson Cancer Center

Dec 5, 2022